BioTissue Holdings has completed the sale of its non-ocular 'Surgical and Wound Care' business to BioStem Technologies, a company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care.

Under the terms of the agreement, BioStem has acquired exclusive rights to the Neox and Clarix product lines. Financial terms of the deal were not disclosed. As part of the transaction, BioTissue’s Surgical sales team and key support staff will join BioStem’s commercial organization. BioTissue will continue to manufacture the products on behalf of BioStem.

Following the divestiture, BioTissue will concentrate its commercial strategy on advancing interventional therapies for acute and chronic ocular surface conditions. The company’s eye care portfolio includes Prokera, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard. 

“Since our founding, our mission has been to transform patient outcomes through regenerative therapies,” said Ted Davis, President and CEO of BioTissue. “This divestiture is a catalyst for our next chapter, one focused squarely on eye care innovation. With a streamlined portfolio and dedicated resources, we are poised to deliver breakthrough solutions and support to our ocular customers and their patients. At the same time, BioStem’s commitment to advancing surgical and wound care applications ensures our technology continues to make a profound impact on physicians and patients across specialties. We are grateful to the Surgical team for their contributions and are excited to see them thrive with BioStem.”